Biomarker-Driven Research: Transforming Treatments for Rare Cancers Reassessing the classification of rare cancer types Historically, research on rare cancers centered around tumor Read Now 
Reflections from ESMO 2025 Progress, Breakthrough Science and the Future of Oncology We were delighted to attend the recent Read Now 
Delivering a Registrational GI Trial Through Ongoing Protocol Shifts An emerging oncology biotech developing next-generation bispecific antibody therapies partnered with Catalyst Oncology to manage Read Now 
Purpose-Built for ADC Development Antibody-drug conjugates (ADCs) are transforming cancer care by combining precision antibody targeting with potent payloads Read Now 
Key Takeaways from ADCs in Oncology Trials Webinar This executive summary captures the key takeaways from a webinar I moderated titled “ADCs in Read Now 
Operationalizing Global Oncology Trials Catalyst Oncology accelerates innovation by aligning strategic insight, deep expertise, a global reach and flawless execution. Read Now 
Specialized Site Network for Early-phase Oncology Success Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Read Now 
Accelerating Approval Pathway For Phase III Ovarian Cancer Trial A late-stage biotech was developing a combination therapy for a rare form of ovarian cancer. It is challenging to diagnose, difficult to treat due to its chemo-resistance, and at the time, there were no approved treatments specifically for this indication. Read Now 
The Resurgence of Antibody-drug Conjugates How ADCs are redefining cancer therapy Cancer treatment is undergoing a transformation, fueled by advances Read Now 
Managing a Multiple CRO Relationship Transition A midsized biotech sponsor approached Catalyst Flex with the opportunity to increase biostatistics and data management work from staff augmentation services only to become their preferred biometrics provider. Read Now